Skip to contentL
Lyell Immunopharma, Inc.
L
LYELLyell Immunopharma, Inc. Q2 2026 · 10-Q
Revenue$4.00K$4.00K−50.0% vs Q2 2025 Net Income-$44.76M-$44.76MN/M vs Q2 2025 EPS Diluted-$1.92-$1.92N/M vs Q2 2025 Operating Income-$47,337,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lyell Immunopharma, Inc. · CIK 1806952 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$34,178,000N/M Margins · derivedOperating margin-1183425.0%−594175.0 pt vs Q2 2025
Net margin-1118875.0%−585325.0 pt vs Q2 2025
ended Jun 30, 2026 · filed Aug 6, 2026 · 37 d after period end